Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant study of 609A + inetetamab + pertuzumab + chemotherapy versus inetetamab + pertuzumab + chemotherapy versus trastuzumab + pertuzumab + chemotherapy in early HER2-positive breast cancer
CTR20222113Phase 2Active
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Aug 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of 609A, inetetamab, pertuzumab, trastuzumab, docetaxel and 1 more in breast cancer (3 arms), sponsored by 3S Guojian Pharmaceutical. Primary endpoint: Pathological complete response. Started Aug 2022; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20222113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222113.